Controlling for anxiety (BAI) and depression (BDI-II), levels of glutamate (F (1, 28) = 20.178, p < 0.001, η2p = 0.419), BDNF (F (1, 28) = 9.784, p < 0.004, η2p = 0.259) and dopamine (F (1, 28) = 19.134, p < 0.001, η2p = 0.406) were significantly lower in patients with FMD than in CTR. Here, BDNF is linked to depressive symptom measurement.